Induced Pluripotent Stem Cells

Companies Induced Pluripotent Stem Cells

BlueRock Therapeutics, USA

BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Th more

News Induced Pluripotent Stem Cells

• Neandertal genes in the petri dish
  

  Protocols that allow the transformation of human induced pluripotent stem cell (iPSC) lines into organoids have changed the way scientists can study developmental processes and enable them to decipher the interplay between genes and tissue formation, particularly for organs where primary tissue is n more

• Induced pluripotent stem cells for the research of HIV and the innate immune system
  

  Jointly with researchers from Germany and France, researchers of the Paul-Ehrlich-Institut have generated induced pluripotent stem cells from one health individual, one patient with Aicardi-Goutières syndrome, and one patient with Renpenning syndrome. Proteins play a role in both diseases, which are more

• Generation of mouse induced pluripotent stem cells succeeds better without Oct4
  

  Quality of induced pluripotent stem cells is dramatically enhanced by omitting what was thought to be the most crucial reprogramming factor. Scientists at the Max Planck Institute for Molecular Biomedicine in Münster showed that Oct4, a factor most commonly used for reprogramming, is detrimental fo more

Publications Induced Pluripotent Stem Cells

• Retraction: Matrix Metalloproteinase-3 in Odontoblastic Cells Derived from Ips Cells: Unique Proliferation Response as Odontoblastic Cells Derived from ES Cells

  by The PLOS ONE Editors more

• [In Depth] iPS cell therapy reported safe

  Japanese researchers reported this week that the first trial of induced pluripotent stem (iPS) cells in a human has proved safe and effective in halting the progression of age-related macular degeneration (AMD), though there was minimal improvement in vision. AMD is the leading cause of vision loss more

• Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system

  Abstract Genome editing research of human ES/iPS cells has been accelerated by clustered regularly interspaced short palindromic repeats/CRISPR-associated 9 (CRISPR/Cas9) and transcription activator-like effector nucleases (TALEN) technologies. However, the efficiency of biallelic genetic engineeri more